Bristol-Myers Squibb Company (BMY)
$69.31
Rating:
Recommendation:
Strong Buy
Symbol | BMY |
---|---|
Price | $69.31 |
Beta | 0.448 |
Volume Avg. | 8.17M |
Market Cap | 145.780B |
Shares () | - |
52 Week Range | 65.28-81.44 |
1y Target Est | - |
DCF Unlevered | BMY DCF -> | |
---|---|---|
DCF Levered | BMY LDCF -> | |
ROE | 19.79% | Buy |
ROA | 6.53% | Neutral |
Operating Margin | - | |
Debt / Equity | 211.53% | Strong Buy |
P/E | 23.49 | Strong Buy |
P/B | 4.70 | Strong Buy |
Latest BMY news
About
Download (Excel)Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.